MARKET

KTTA

KTTA

Pasithea Therapeutics Corp
NASDAQ
0.4805
+0.0025
+0.52%
After Hours: 0.4900 +0.0095 +1.98% 17:09 08/14 EDT
OPEN
0.4780
PREV CLOSE
0.4780
HIGH
0.4947
LOW
0.4764
VOLUME
43.25K
TURNOVER
--
52 WEEK HIGH
2.060
52 WEEK LOW
0.2810
MARKET CAP
16.06M
P/E (TTM)
-0.2431
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KTTA last week (0803-0807)?
Weekly Report · 6d ago
Weekly Report: what happened at KTTA last week (0727-0731)?
Weekly Report · 08/03 09:21
Analysts Offer Insights on Healthcare Companies: Pasithea Therapeutics Corp (KTTA), Crescent Biopharma (CBIO) and Dexcom (DXCM)
TipRanks · 07/31 10:30
Weekly Report: what happened at KTTA last week (0720-0724)?
Weekly Report · 07/27 09:23
Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026
Benzinga · 07/21 11:20
Weekly Report: what happened at KTTA last week (0713-0717)?
Weekly Report · 07/20 09:22
New Strong Buy Stocks for July 20th
NASDAQ · 07/20 09:03
Weekly Report: what happened at KTTA last week (0706-0710)?
Weekly Report · 07/13 09:22
More
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTA stock methods without spending real money on the virtual paper trading platform.